Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Chemically Modified Derivatives of the Activator Compound Cloxyquin Exert Inhibitory Effect on TRESK (K2P18.1) Background Potassium Channel.

Lengyel M, Erdélyi F, Pergel E, Bálint-Polonka Á, Dobolyi A, Bozsaki P, Dux M, Király K, Hegedűs T, Czirják G, Mátyus P, Enyedi P.

Mol Pharmacol. 2019 Jun;95(6):652-660. doi: 10.1124/mol.118.115626. Epub 2019 Apr 12.

PMID:
30979812
2.

[Multiple sclerosis in central Hungary: experiences and future possibilities of developing a local database].

Iljicsov A, Simó M, Tegze N, Szócska M, Mátyus P, Bereczki D.

Orv Hetil. 2019 Jan;160(4):131-137. doi: 10.1556/650.2019.31274. Hungarian.

PMID:
30661382
3.

[Databases in neurological diseases: overview of international examples in multiple sclerosis].

Iljicsov A, Simó M, Tegze N, Szócska M, Mátyus P, Bereczki D.

Orv Hetil. 2019 Jan;160(4):123-130. doi: 10.1556/650.2019.31273. Hungarian.

PMID:
30661380
4.

HPLC-ECD and TDDFT-ECD study of hexahydropyrrolo[1,2-a]quinoline derivatives.

Tóth L, Mándi A, Váradi D, Kovács T, Szabados A, Kiss-Szikszai A, Gong Q, Zhang H, Mátyus P, Antus S, Kurtán T.

Chirality. 2018 Jul;30(7):866-874. doi: 10.1002/chir.22969. Epub 2018 May 12.

PMID:
29752732
5.

Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors.

Horváth Á, Tékus V, Bencze N, Szentes N, Scheich B, Bölcskei K, Szőke É, Mócsai A, Tóth-Sarudy É, Mátyus P, Pintér E, Helyes Z.

Pharmacol Res. 2018 May;131:231-243. doi: 10.1016/j.phrs.2018.02.006. Epub 2018 Feb 10.

PMID:
29438782
6.

Different electrophysiological effects of the levo- and dextro-rotatory isomers of mexiletine in isolated rabbit cardiac muscle.

Gurabi Z, Patocskai B, Györe B, Virág L, Mátyus P, Papp JG, Varró A, Koncz I.

Can J Physiol Pharmacol. 2017 Jul;95(7):830-836. doi: 10.1139/cjpp-2016-0599. Epub 2017 Feb 22.

PMID:
28226224
7.

Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.

Meleddu R, Distinto S, Cirilli R, Alcaro S, Yanez M, Sanna ML, Corona A, Melis C, Bianco G, Matyus P, Cottiglia F, Maccioni E.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):264-270. doi: 10.1080/14756366.2016.1247061.

8.

Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse.

Horváth Á, Menghis A, Botz B, Borbély É, Kemény Á, Tékus V, Csepregi JZ, Mócsai A, Juhász T, Zákány R, Bogdán D, Mátyus P, Keeble J, Pintér E, Helyes Z.

Sci Rep. 2017 Jan 9;7:39863. doi: 10.1038/srep39863.

9.

The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.

Obuobi S, Karatayev S, Chai CL, Ee PL, Mátyus P.

J Enzyme Inhib Med Chem. 2016;31(sup3):194-204. Epub 2016 Jul 7. Review.

PMID:
27389167
10.

A novel 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist.

Payrits M, Sághy É, Mátyus P, Czompa A, Ludmerczki R, Deme R, Sándor Z, Helyes Z, Szőke É.

Neuroscience. 2016 Jun 2;324:151-62. doi: 10.1016/j.neuroscience.2016.02.049. Epub 2016 Feb 27.

PMID:
26930003
11.

Dietary Phenolic Compounds Interfere with the Fate of Hydrogen Peroxide in Human Adipose Tissue but Do Not Directly Inhibit Primary Amine Oxidase Activity.

Carpéné C, Hasnaoui M, Balogh B, Matyus P, Fernández-Quintela A, Rodríguez V, Mercader J, Portillo MP.

Oxid Med Cell Longev. 2016;2016:2427618. doi: 10.1155/2016/2427618. Epub 2016 Jan 5.

12.

[Editor's commentary: Bionics Innovation Center, Budapest, Hungary].

Mátyus P.

Orv Hetil. 2015 Dec 27;156(52):2095. Hungarian. No abstract available.

PMID:
26785508
13.

Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.

Baranyi M, Porceddu PF, Gölöncsér F, Kulcsár S, Otrokocsi L, Kittel Á, Pinna A, Frau L, Huleatt PB, Khoo ML, Chai CL, Dunkel P, Mátyus P, Morelli M, Sperlágh B.

Mol Neurodegener. 2016 Jan 13;11:6. doi: 10.1186/s13024-015-0067-y.

14.

Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida.

Meleddu R, Distinto S, Corona A, Maccioni E, Arridu A, Melis C, Bianco G, Matyus P, Cottiglia F, Sanna A, De Logu A.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1672-7. doi: 10.3109/14756366.2015.1113171. Epub 2016 Jan 8.

PMID:
26745285
15.

Light-Enhanced Fluorescence of Multi-Level Cavitands Possessing Pyridazine Upper rim.

Janosi TZ, Makkai G, Kegl T, Matyus P, Kollar L, Erostyak J.

J Fluoresc. 2016 Mar;26(2):679-88. doi: 10.1007/s10895-015-1754-3. Epub 2015 Dec 29.

PMID:
26715516
16.

One size does not fit all: Challenging some dogmas and taboos in drug discovery.

Chai CL, Mátyus P.

Future Med Chem. 2016 Jan;8(1):29-38. doi: 10.4155/fmc.15.167. Epub 2015 Dec 21. Review.

PMID:
26689236
17.

[From biomarkers to clinical decision support].

Antal P, Reiter J, Mátyus P.

Orv Hetil. 2015 Dec 20;156(51):2077-81. doi: 10.1556/650.2015.30320. Review. Hungarian.

PMID:
26654544
18.

[Editor's commentary: Bionics Innovation Center, Budapest, Hungary].

Mátyus P.

Orv Hetil. 2015 Dec 20;156(51):2059. doi: 10.1556/650.2015.30352. Hungarian. No abstract available.

PMID:
26654540
19.

Metabolism-Activated Multitargeting (MAMUT): An Innovative Multitargeting Approach to Drug Design and Development.

Mátyus P, Chai CL.

ChemMedChem. 2016 Jun 20;11(12):1197-8. doi: 10.1002/cmdc.201500406. Epub 2015 Oct 26.

PMID:
26497424
20.

Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions.

Hanuska A, Szénási G, Albert M, Koles L, Varga A, Szabo A, Matyus P, Harsing LG Jr.

Neurochem Res. 2016 Feb;41(1-2):73-85. doi: 10.1007/s11064-015-1713-z. Epub 2015 Sep 12.

PMID:
26364050
21.

Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action.

Parrino B, Carbone A, Ciancimino C, Spanò V, Montalbano A, Barraja P, Cirrincione G, Diana P, Sissi C, Palumbo M, Pinato O, Pennati M, Beretta G, Folini M, Matyus P, Balogh B, Zaffaroni N.

Eur J Med Chem. 2015 Apr 13;94:149-62. doi: 10.1016/j.ejmech.2015.03.005. Epub 2015 Mar 5.

PMID:
25768699
22.

(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.

Meleddu R, Distinto S, Corona A, Bianco G, Cannas V, Esposito F, Artese A, Alcaro S, Matyus P, Bogdan D, Cottiglia F, Tramontano E, Maccioni E.

Eur J Med Chem. 2015 Mar 26;93:452-60. doi: 10.1016/j.ejmech.2015.02.032. Epub 2015 Feb 20.

PMID:
25728026
23.

Analysis of Edg-Like LPA Receptor-Ligand Interactions.

Balogh B, Pazmany T, Matyus P.

Curr Pharm Des. 2015;21(24):3533-47.

PMID:
25686617
24.

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.

Huleatt PB, Khoo ML, Chua YY, Tan TW, Liew RS, Balogh B, Deme R, Gölöncsér F, Magyar K, Sheela DP, Ho HK, Sperlágh B, Mátyus P, Chai CL.

J Med Chem. 2015 Feb 12;58(3):1400-19. doi: 10.1021/jm501722s. Epub 2015 Jan 28.

PMID:
25627172
25.

Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.

Harsing LG Jr, Timar J, Szabo G, Udvari S, Nagy KM, Marko B, Zsilla G, Czompa A, Tapolcsanyi P, Kocsis A, Matyus P.

Curr Pharm Des. 2015;21(17):2291-303.

PMID:
25578890
26.

Preparation of neuroprotective condensed 1,4-benzoxazepines by regio- and diastereoselective domino Knoevenagel-[1,5]-hydride shift cyclization reaction.

Tóth L, Fu Y, Zhang HY, Mándi A, Kövér KE, Illyés TZ, Kiss-Szikszai A, Balogh B, Kurtán T, Antus S, Mátyus P.

Beilstein J Org Chem. 2014 Nov 6;10:2594-602. doi: 10.3762/bjoc.10.272. eCollection 2014.

27.

Anti-inflammatory effects of a triple-bond resveratrol analog: structure and function relationship.

Antus C, Radnai B, Dombovari P, Fonai F, Avar P, Matyus P, Racz B, Sumegi B, Veres B.

Eur J Pharmacol. 2015 Feb 5;748:61-7. doi: 10.1016/j.ejphar.2014.12.009. Epub 2014 Dec 18.

PMID:
25528327
28.

Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy.

Temesi G, Bolgár B, Arany A, Szalai C, Antal P, Mátyus P.

Future Med Chem. 2014 Apr;6(5):563-75. doi: 10.4155/fmc.14.4.

PMID:
24649958
29.

Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies.

Bolgár B, Arany Á, Temesi G, Balogh B, Antal P, Mátyus P.

Curr Top Med Chem. 2013;13(18):2337-63. Review.

PMID:
24059461
30.

CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells.

Kósa JP, Horváth P, Wölfling J, Kovács D, Balla B, Mátyus P, Horváth E, Speer G, Takács I, Nagy Z, Horváth H, Lakatos P.

World J Gastroenterol. 2013 May 7;19(17):2621-8. doi: 10.3748/wjg.v19.i17.2621.

31.

Imidazoline versus alpha₂-adrenoceptors in the control of gastric motility in mice.

Zádori ZS, Fehér Á, Al-Khrasani M, Lackó E, Tóth VE, Brancati SB, Hein L, Mátyus P, Gyires K.

Eur J Pharmacol. 2013 Apr 5;705(1-3):61-7. doi: 10.1016/j.ejphar.2013.02.043. Epub 2013 Mar 13.

PMID:
23499689
32.

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model.

Énzsöly A, Markó K, Tábi T, Szökő É, Zelkó R, Tóth M, Petrash JM, Mátyus P, Németh J.

J Neural Transm (Vienna). 2013 Jun;120(6):969-75. doi: 10.1007/s00702-013-0986-0. Epub 2013 Feb 9.

33.

Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.

Ilić M, Dunkel P, Ilaš J, Chabielska E, Zakrzeska A, Mátyus P, Kikelj D.

Eur J Med Chem. 2013 Apr;62:329-40. doi: 10.1016/j.ejmech.2013.01.002. Epub 2013 Jan 10.

PMID:
23376251
34.

Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters.

Harsing LG Jr, Matyus P.

Brain Res Bull. 2013 Apr;93:110-9. doi: 10.1016/j.brainresbull.2012.12.002. Epub 2012 Dec 22. Review.

PMID:
23266673
35.

Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation.

Tábi T, Szökő E, Mérey A, Tóth V, Mátyus P, Gyires K.

J Neural Transm (Vienna). 2013 Jun;120(6):963-7. doi: 10.1007/s00702-012-0961-1. Epub 2012 Dec 21.

PMID:
23263543
36.

Multi-aspect candidates for repositioning: data fusion methods using heterogeneous information sources.

Arany Á, Bolgár B, Balogh B, Antal P, Mátyus P.

Curr Med Chem. 2013;20(1):95-107.

PMID:
23210850
37.

Temporal alteration of spreading depression by the glycine transporter type-1 inhibitors NFPS and Org-24461 in chicken retina.

Kertesz S, Szabo G, Udvari S, Levay G, Matyus P, Harsing LG Jr.

Brain Res. 2013 Jan 25;1492:1-6. doi: 10.1016/j.brainres.2012.11.025. Epub 2012 Nov 23.

PMID:
23178696
38.

Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis.

Ilić M, Ilaš J, Dunkel P, Mátyus P, Boháč A, Liekens S, Kikelj D.

Eur J Med Chem. 2012 Dec;58:160-70. doi: 10.1016/j.ejmech.2012.10.001. Epub 2012 Oct 8.

PMID:
23124213
39.

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.

Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308. doi: 10.1517/13543784.2012.703178. Epub 2012 Jun 28. Review.

PMID:
22741814
40.

Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review).

Harsing LG, Zsilla G, Matyus P, Nagy KM, Marko B, Gyarmati Z, Timar J.

Acta Physiol Hung. 2012 Mar;99(1):1-17. doi: 10.1556/APhysiol.99.2012.1.1. Review.

PMID:
22425803
41.

Inhibition of hypoxia-induced [(3)H]glycine release from chicken retina by the glycine transporter type-1 (GlyT-1) inhibitors NFPS and Org-24461.

Harsing LG Jr, Albert M, Matyus P, Szenasi G.

Exp Eye Res. 2012 Jan;94(1):6-12. doi: 10.1016/j.exer.2011.10.010. Epub 2011 Nov 9.

PMID:
22079563
42.

3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B.

Maccioni E, Alcaro S, Cirilli R, Vigo S, Cardia MC, Sanna ML, Meleddu R, Yanez M, Costa G, Casu L, Matyus P, Distinto S.

J Med Chem. 2011 Sep 22;54(18):6394-8. doi: 10.1021/jm2002876. Epub 2011 Aug 17.

PMID:
21777011
43.

Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey.

Dunkel P, Balogh B, Meleddu R, Maccioni E, Gyires K, Mátyus P.

Expert Opin Ther Pat. 2011 Sep;21(9):1453-71. doi: 10.1517/13543776.2011.594040. Epub 2011 Jun 15. Review.

PMID:
21675926
44.

SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders.

Mercader J, Iffiú-Soltesz Z, Brenachot X, Földi A, Dunkel P, Balogh B, Attané C, Valet P, Mátyus P, Carpéné C.

Future Med Chem. 2010 Dec;2(12):1735-49. doi: 10.4155/fmc.10.260.

PMID:
21428797
45.

Welcome to new insights into 'Metabolic Syndrome'.

Matyus P.

Future Med Chem. 2010 Dec;2(12):1719-20. doi: 10.4155/fmc.10.269. No abstract available.

46.

α(2)-adrenoceptor agonist-induced inhibition of gastric motor activity is mediated by α(2A)-adrenoceptor subtype in the mouse.

Shujaa N, Al-Khrasani M, Zádori ZS, Rossi M, Mátyus P, Németh J, Hein L, Gyires K.

Neurochem Int. 2011 May;58(6):708-13. doi: 10.1016/j.neuint.2011.02.011. Epub 2011 Feb 17.

PMID:
21333706
47.

Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization.

Enzsöly A, Dunkel P, Récsán Z, Gyorffy H, Tóth J, Marics G, Bori Z, Tóth M, Zelkó R, Di Paolo ML, Mátyus P, Németh J.

J Neural Transm (Vienna). 2011 Jul;118(7):1065-9. doi: 10.1007/s00702-011-0595-8. Epub 2011 Feb 18.

PMID:
21331460
48.

Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, Juranyi Z, Barkoczy J, Levay G, Harsing LG Jr.

Neurochem Res. 2010 Dec;35(12):2096-106. doi: 10.1007/s11064-010-0241-0. Epub 2010 Aug 20.

PMID:
20725779
49.

Synthesis of ortho-functionalized 4-aminomethylpyridazines as substrate-like semicarbazide-sensitive amine oxidase inhibitors.

Haider N, Hochholdinger I, Mátyus P, Wobus A.

Chem Pharm Bull (Tokyo). 2010 Jul;58(7):964-70.

50.

Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.

Van Baelen G, Hostyn S, Dhooghe L, Tapolcsányi P, Mátyus P, Lemière G, Dommisse R, Kaiser M, Brun R, Cos P, Maes L, Hajós G, Riedl Z, Nagy I, Maes BU, Pieters L.

Bioorg Med Chem. 2009 Oct 15;17(20):7209-17. doi: 10.1016/j.bmc.2009.08.057. Epub 2009 Sep 3.

PMID:
19781948

Supplemental Content

Loading ...
Support Center